Last reviewed · How we verify
P-Gemox
P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | P-Gemox |
|---|---|
| Also known as | Pegaspargase, gemcitabine, oxaliplatin |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Combination chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen pairs gemcitabine, a nucleoside analog that disrupts DNA replication, with oxaliplatin, a platinum-based agent that forms DNA crosslinks. Together, these agents work synergistically to prevent cancer cell proliferation and survival. The combination is designed to improve efficacy over single-agent therapy in solid tumors.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
Key clinical trials
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (PHASE2)
- Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma (PHASE2)
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (PHASE3)
- A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. (PHASE3)
- A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) (PHASE3)
- Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P-Gemox CI brief — competitive landscape report
- P-Gemox updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI